Advertisement
Screener

INVIVYD, INC. (IVVD) Depreciation

2.8 / 5 stars · 68/120 Roast Me

INVIVYD, INC. Depreciation

INVIVYD, INC. (IVVD) reported Depreciation of $382.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:Depreciation · last filed 2024-11-14

  • INVIVYD, INC. depreciation for the quarter ending 2024-09-30 was $132.00K, a 10.92% increase year-over-year.
  • INVIVYD, INC. depreciation for the quarter ending 2024-06-30 was $128.00K, a 5.79% increase year-over-year.
  • INVIVYD, INC. depreciation for the quarter ending 2024-03-31 was $122.00K, a 1.67% increase year-over-year.
  • INVIVYD, INC. depreciation for the quarter ending 2023-12-31 was $120.00K, a 344.44% increase year-over-year.
  • INVIVYD, INC. depreciation for fiscal 2023 was $480.00K, a 1070.73% increase from fiscal 2022.
  • INVIVYD, INC. depreciation for fiscal 2022 was $41.00K.
Period endDepreciation 3 monthDepreciation 6 monthDepreciation 7 monthDepreciation 9 monthDepreciation 12 month
2024-09-30$132.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$260.00K
derived: sum of 2 quarters · filed 2024-11-14
$382.00K
10-Q · filed 2024-11-14
$502.00K
derived: sum of 4 quarters · filed 2024-11-14
2024-06-30$128.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
$250.00K
10-Q · filed 2024-08-14
$370.00K
derived: sum of 3 quarters · filed 2024-08-14
$489.00K
derived: sum of 4 quarters · filed 2024-11-14
2024-03-31$122.00K
10-Q · filed 2024-05-09
$242.00K
derived: sum of 2 quarters · filed 2024-05-09
$361.00K
derived: sum of 3 quarters · filed 2024-11-14
$482.00K
derived: sum of 4 quarters · filed 2024-11-14
2023-12-31$120.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
$239.00K
derived: sum of 2 quarters · filed 2024-11-14
$360.00K
derived: sum of 3 quarters · filed 2024-11-14
$480.00K
10-K · filed 2024-03-28
2023-09-30$119.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$240.00K
derived: sum of 2 quarters · filed 2024-11-14
$360.00K
10-Q · filed 2024-11-14
$387.00K
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$121.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
$241.00K
10-Q · filed 2024-08-14
$268.00K
derived: sum of 3 quarters · filed 2024-08-14
$273.00K
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31$120.00K
10-Q · filed 2024-05-09
$147.00K
derived: sum of 2 quarters · filed 2024-05-09
$152.00K
derived: sum of 3 quarters · filed 2024-05-09
$157.00K
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31$27.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
$32.00K
derived: sum of 2 quarters · filed 2024-03-28
$37.00K
derived: sum of 3 quarters · filed 2024-03-28
$41.00K
10-K · filed 2024-03-28
2022-09-30$5.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$10.00K
derived: sum of 2 quarters · filed 2023-11-09
$14.00K
10-Q · filed 2023-11-09
$15.00K
derived: sum of 4 quarters · filed 2024-02-09
2022-06-30$5.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$9.00K
10-Q · filed 2023-08-10
$10.00K
derived: sum of 3 quarters · filed 2024-02-09
$10.00K
derived: sum of 4 quarters · filed 2024-02-09
2022-03-31$4.00K
10-Q · filed 2023-05-11
$5.00K
derived: sum of 2 quarters · filed 2024-02-09
$5.00K
derived: sum of 3 quarters · filed 2024-02-09
$5.00K
derived: sum of 4 quarters · filed 2024-02-09
2021-12-31$1.00K
derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09
$1.00K
derived: sum of 2 quarters · filed 2024-02-09
$1.00K
derived: sum of 3 quarters · filed 2024-02-09
$1.00K
8-K · filed 2024-02-09
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
$0.00
derived: sum of 2 quarters · filed 2022-11-10
$0.00
10-Q · filed 2022-11-10
2021-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
$0.00
10-Q · filed 2022-08-15
2021-03-31$0.00
10-Q · filed 2022-05-13
2020-12-31$0.00
10-K · filed 2022-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Liminatus Pharma, Inc. (LIMN)United States$0.282B
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49